Individual determinations of %V617F over time in the 29 mutated patients
Patient no. . | 9pLOH . | Month 0 . | Month 6 . | Month 12 . | Month 18 . | Month 24 . | Month 30 . | Month 36 . |
---|---|---|---|---|---|---|---|---|
1 | 50 | 15 | 10 | 10 | 10 | 10 | 5 | |
2 | 20 | 5 | 5 | ND | 1 | 0 | 0 | |
3 | − | 50 | 40 | 40 | 25 | 20 | 10 | 10 |
4 | + | 100 | 50 | 50 | 45 | 45 | 45 | 40 |
5 | 40 | 40 | 20 | 20 | 20 | 15 | 5 | |
6 | 50 | 50 | 0 | 0 | 0 | 0 | ||
7 | 100 | 50 | 45 | 30 | ||||
8 | 25 | 25 | 10 | 5 | 5* | 5* | ||
9 | 100 | 85 | 50 | 15 | 5 | 0* | 0* | |
10 | + | 70 | 55 | 45 | ||||
11 | 40 | 40 | 40 | 40* | ||||
12 | 10 | 5 | 5 | 5* | 5* | 0* | 0* | |
13 | − | 40 | 25 | 25 | 25 | 25 | ||
14 | 40 | 25 | 20 | 20 | ||||
15 | + | 50 | 45 | 30 | 30 | |||
16 | + | 80 | 45 | 25 | ND | 10 | 10 | 1 |
17 | + | 45 | 35 | 25 | ND | 5 | ||
18 | + | 60 | 60 | 45 | 10* | 10* | ||
19 | − | 40 | 20 | 20 | 5 | 5 | 5 | |
20 | − | 20 | 20 | 10 | 5 | 5* | 5* | |
21 | 35 | 20 | 20 | 10 | 1 | 1 | ||
22 | − | 20 | 10 | 5 | 0* | |||
23 | 10 | 10 | 10 | ND | 10 | |||
24 | − | 40 | 10 | 10 | 5 | 1 | ||
25 | + | 65 | 45 | 45 | ND* | 0* | 0* | |
26 | 50 | ND | 50 | 40* | ||||
27 | 45 | 25 | ND | 25 | 25 | |||
28 | − | 65 | 50 | 50 | 50 | |||
29 | − | 45 | 10 | 0 | 0* | 0* | 0* |
Patient no. . | 9pLOH . | Month 0 . | Month 6 . | Month 12 . | Month 18 . | Month 24 . | Month 30 . | Month 36 . |
---|---|---|---|---|---|---|---|---|
1 | 50 | 15 | 10 | 10 | 10 | 10 | 5 | |
2 | 20 | 5 | 5 | ND | 1 | 0 | 0 | |
3 | − | 50 | 40 | 40 | 25 | 20 | 10 | 10 |
4 | + | 100 | 50 | 50 | 45 | 45 | 45 | 40 |
5 | 40 | 40 | 20 | 20 | 20 | 15 | 5 | |
6 | 50 | 50 | 0 | 0 | 0 | 0 | ||
7 | 100 | 50 | 45 | 30 | ||||
8 | 25 | 25 | 10 | 5 | 5* | 5* | ||
9 | 100 | 85 | 50 | 15 | 5 | 0* | 0* | |
10 | + | 70 | 55 | 45 | ||||
11 | 40 | 40 | 40 | 40* | ||||
12 | 10 | 5 | 5 | 5* | 5* | 0* | 0* | |
13 | − | 40 | 25 | 25 | 25 | 25 | ||
14 | 40 | 25 | 20 | 20 | ||||
15 | + | 50 | 45 | 30 | 30 | |||
16 | + | 80 | 45 | 25 | ND | 10 | 10 | 1 |
17 | + | 45 | 35 | 25 | ND | 5 | ||
18 | + | 60 | 60 | 45 | 10* | 10* | ||
19 | − | 40 | 20 | 20 | 5 | 5 | 5 | |
20 | − | 20 | 20 | 10 | 5 | 5* | 5* | |
21 | 35 | 20 | 20 | 10 | 1 | 1 | ||
22 | − | 20 | 10 | 5 | 0* | |||
23 | 10 | 10 | 10 | ND | 10 | |||
24 | − | 40 | 10 | 10 | 5 | 1 | ||
25 | + | 65 | 45 | 45 | ND* | 0* | 0* | |
26 | 50 | ND | 50 | 40* | ||||
27 | 45 | 25 | ND | 25 | 25 | |||
28 | − | 65 | 50 | 50 | 50 | |||
29 | − | 45 | 10 | 0 | 0* | 0* | 0* |
LOH indicates loss of heterozygosity; and ND, not done.
Samples taken after peg-IFNα -2a discontinuation.